Haley J Appaneal1,2,3, Aisling R Caffrey1,2,3,4, Maya Beganovic1,2, Sanja Avramovic5, Kerry L LaPlante1,2,3,6. 1. Infectious Diseases Research Program, Providence Veterans Affairs Medical Center, Providence, Rhode Island. 2. College of Pharmacy, University of Rhode Island, Kingston, Rhode Island. 3. Center of Innovation in Long-Term Support Services, Providence Veterans Affairs Medical Center, Providence, Rhode Island. 4. Brown University School of Public Health, Providence, Rhode Island. 5. Health Administration and Policy, George Mason University, Fairfax, Virginia. 6. Division of Infectious Diseases, Warren Alpert Medical School of Brown University, Providence, Rhode Island.
Abstract
BACKGROUND: Though recurrent Clostridium difficile infection (CDI) is common and poses a major clinical concern, data are lacking regarding mortality among patients who survive their initial CDI and have subsequent recurrences. Risk factors for mortality in patients with recurrent CDI are largely unknown. METHODS: Veterans Affairs patients with a first CDI (stool sample with positive C. difficile toxin(s) and ≥2 days CDI treatment) were included (2010-2014). Subsequent recurrences were defined as additional CDI episodes ≥14 days after the stool test date and within 30 days of the end of treatment. A matched (1:4) case-control analysis was conducted using multivariable conditional logistic regression to identify predictors of all-cause mortality within 30 days of the first recurrence. RESULTS: Crude 30-day all-cause mortality rates were 10.6% for the initial CDI episode, 8.3% for the first recurrence, 4.2% for the second recurrence, and 5.9% for the third recurrence. Among 110 cases and 440 controls, 6 predictors of mortality were identified: use of proton pump inhibitors (PPIs; odds ratio [OR], 3.86; 95% confidence interval [CI], 2.14-6.96), any antibiotic (OR, 3.33; 95% CI, 1.79-6.17), respiratory failure (OR, 8.26; 95% CI, 1.71-39.92), congitive dysfunction (OR, 2.41; 95% CI, 1.02-5.72), nutrition deficiency (OR, 2.91; 95% CI, 1.37-6.21), and age (OR, 1.04; 95% CI, 1.01-1.07). CONCLUSIONS: In our national cohort of Veterans, crude mortality decreased by 44% from the initial episode to the third recurrence. Treatment with antibiotics, use of PPIs, and underlying comorbidities were important predictors of mortality in recurrent CDI. Our study assists health care providers in identifying patients at high risk of death after CDI recurrence.
BACKGROUND: Though recurrent Clostridium difficile infection (CDI) is common and poses a major clinical concern, data are lacking regarding mortality among patients who survive their initial CDI and have subsequent recurrences. Risk factors for mortality in patients with recurrent CDI are largely unknown. METHODS: Veterans Affairs patients with a first CDI (stool sample with positive C. difficile toxin(s) and ≥2 days CDI treatment) were included (2010-2014). Subsequent recurrences were defined as additional CDI episodes ≥14 days after the stool test date and within 30 days of the end of treatment. A matched (1:4) case-control analysis was conducted using multivariable conditional logistic regression to identify predictors of all-cause mortality within 30 days of the first recurrence. RESULTS: Crude 30-day all-cause mortality rates were 10.6% for the initial CDI episode, 8.3% for the first recurrence, 4.2% for the second recurrence, and 5.9% for the third recurrence. Among 110 cases and 440 controls, 6 predictors of mortality were identified: use of proton pump inhibitors (PPIs; odds ratio [OR], 3.86; 95% confidence interval [CI], 2.14-6.96), any antibiotic (OR, 3.33; 95% CI, 1.79-6.17), respiratory failure (OR, 8.26; 95% CI, 1.71-39.92), congitive dysfunction (OR, 2.41; 95% CI, 1.02-5.72), nutrition deficiency (OR, 2.91; 95% CI, 1.37-6.21), and age (OR, 1.04; 95% CI, 1.01-1.07). CONCLUSIONS: In our national cohort of Veterans, crude mortality decreased by 44% from the initial episode to the third recurrence. Treatment with antibiotics, use of PPIs, and underlying comorbidities were important predictors of mortality in recurrent CDI. Our study assists health care providers in identifying patients at high risk of death after CDI recurrence.
Authors: Christina M Surawicz; Lawrence J Brandt; David G Binion; Ashwin N Ananthakrishnan; Scott R Curry; Peter H Gilligan; Lynne V McFarland; Mark Mellow; Brian S Zuckerbraun Journal: Am J Gastroenterol Date: 2013-02-26 Impact factor: 10.864
Authors: Vanessa W Stevens; Richard E Nelson; Elyse M Schwab-Daugherty; Karim Khader; Makoto M Jones; Kevin A Brown; Tom Greene; Lindsay D Croft; Melinda Neuhauser; Peter Glassman; Matthew Bidwell Goetz; Matthew H Samore; Michael A Rubin Journal: JAMA Intern Med Date: 2017-04-01 Impact factor: 21.873
Authors: David W Eyre; A Sarah Walker; David Wyllie; Kate E Dingle; David Griffiths; John Finney; Lily O'Connor; Alison Vaughan; Derrick W Crook; Mark H Wilcox; Timothy E A Peto Journal: Clin Infect Dis Date: 2012-08 Impact factor: 9.079
Authors: Nieves Sopena; Jun Hao Wang-Wang; Irma Casas; Lourdes Mateu; Laia Castellà; María José García-Quesada; Sara Gutierrez; Josep M Llibre; M Luisa Pedro-Botet; Gema Fernandez-Rivas Journal: Microorganisms Date: 2022-05-23
Authors: Scott J Douglas; Ethan A Remily; Oliver C Sax; Sahir S Pervaiz; Evan B Polsky; Ronald E Delanois Journal: Clin Orthop Relat Res Date: 2021-12-01 Impact factor: 4.176
Authors: Cristina V Cardemil; Neha Balachandran; Anita Kambhampati; Scott Grytdal; Rebecca M Dahl; Maria C Rodriguez-Barradas; Blanca Vargas; David O Beenhouwer; Karen V Evangelista; Vincent C Marconi; Kathryn L Meagley; Sheldon T Brown; Adrienne Perea; Cynthia Lucero-Obusan; Mark Holodniy; Hannah Browne; Rashi Gautam; Michael D Bowen; Jan Vinjé; Umesh D Parashar; Aron J Hall Journal: Clin Infect Dis Date: 2021-11-02 Impact factor: 20.999
Authors: Jacek Czepiel; Marcela Krutova; Assaf Mizrahi; Nagham Khanafer; David A Enoch; Márta Patyi; Aleksander Deptuła; Antonella Agodi; Xavier Nuvials; Hanna Pituch; Małgorzata Wójcik-Bugajska; Iwona Filipczak-Bryniarska; Bartosz Brzozowski; Marcin Krzanowski; Katarzyna Konturek; Marcin Fedewicz; Mateusz Michalak; Lorra Monpierre; Philippe Vanhems; Theodore Gouliouris; Artur Jurczyszyn; Sarah Goldman-Mazur; Dorota Wultańska; Ed J Kuijper; Jan Skupień; Grażyna Biesiada; Aleksander Garlicki Journal: Antibiotics (Basel) Date: 2021-03-13
Authors: Haley J Appaneal; Theresa I Shireman; Vrishali V Lopes; Vincent Mor; David M Dosa; Kerry L LaPlante; Aisling R Caffrey Journal: BMC Geriatr Date: 2021-07-23 Impact factor: 3.921